free html web templates

Clinical Oncology

Every cancer is distinct. Let’s handle it accordingly

Knowing a patient’s biomarker profile can uncover novel targets for therapies.

Our Clinical diagnostic panels provide valuable insights on clinically relevant alterations in DNA that drive cancer growth.

Help transform targeted therapy, immunotherapy and chemotherapy clinical trials into viable cancer treatment options.

All our clinical samples are processed at CAP accredited & CLIA certified labs

Our OncoXplore panels by NGS, captures mutations, deletions, Copy Number Variations (CNV) and rearrangements for which target and Biologic therapies are approved, and are being clinically tested.

Mobirise

OncoXplore Comprehensive Panel for Somatic Solid Tumor 

Coding regions of 468 genes & introns of 43 genes

Who Benefits from
OncoXplore Comprehensive Somatic Panel?

1

Individuals with advanced or late stage cancers.

2

Individuals who have tested negative for single gene mutations and require a more comprehensive tumor profiling.

3

Individuals with cancers of unknown primary origin. 

4

Individuals with inadequate amount of tissue or unobtainable tissue for biopsy.

OncoXplore Comprehensive Panel interrogates 

  • Complete coding regions of 468 genes and the introns of 43 genes.
  • Detects all four types of genomic abnormalities (SNV, InDel, CNV and Fusion) and also generate results (TMB, bTMB and MSI) that can help guide cancer immunotherapies.

OncoXplore Non-small cell lung cancer (NSCLC) Panel

NSCLC Panel interrogates the complete coding region of 47 genes & introns of 9 genes covering the fusion genes.

Who Benefits from
OncoXplore NSCLC Panel?

NSCLC Panel is suitable for all NSCLC patients, especially for the following:

1

Patients newly diagnosed with Non-Small Cell Lung Cancer (NSCLC).

2

NSCLC patients with drug resistance to multiple types of chemotherapy.                                 

3

NSCLC patients planning to use targeted therapy.

4

NSCLC patients who are treated with chemotherapies and would like to know the efficacy and toxicity of these drugs.

OncoXplore NSCLC Panel interrogates 

  • Complete coding region of 47 genes and introns of 9 genes.
  • Detect all four types of genomic abnormalities (SNV, InDel, CNV and fusion) and provide targeted therapy options.
  • In addition, it analyzes pharmacogenomics and provides chemotherapy options.

OncoXplore
Colorectal cancer Panel

Colorectal cancer Panel interrogates the complete coding region of 50 genes & introns of 10 genes

Who Benefits from
OncoXplore Colorectal Cancer  Panel?

Colorectal cancer Panel is suitable for all CRC patients, especially for the following:

1

Patients newly diagnosed with Colorectal Cancer (CRC).

2

CRC patients with drug resistance to multiple types of chemotherapy.                                 

3

CRC patients planning to use targeted therapy.

4

CRC patients who are treated with chemotherapies and would like to know the efficacy and toxicity of these drugs.

OncoXplore Colorectal Cancer Panel interrogates 

  • Complete coding region of 50 genes and introns of 10 genes.
  • Detect genomic abnormalities (SNV, InDel, CNV and Fusion) and MSI and provide targeted therapy/immunotherapy options.
  • In addition, it analyzes pharmacogenomics and provides chemotherapy options.

OncoXplore
Breast & Ovarian Cancers

OncoXplore Breast & Ovarian Cancers Panel interrogates the complete coding region of 45 genes for Breast & Ovarian Cancers 

Who Benefits from
OncoXplore Breast & Ovarian Cancer Panel?

All breast cancer patients and ovarian cancer patients are highly recommended to have the test, especially for the following patients:

1

Breast cancer patients with HER2-negative tumors.

2

Breast cancer patients with triple-negative tumors.

3

Patients with platinum-sensitive or platinum-resistant ovarian cancer who have been treated with two or more lines of chemotherapy.

OncoXplore Breast & Ovarian Cancer Panel interrogates 

  • 45 genes for Breast & Ovarian Cancers.
  • Detect genomic abnormalities (SNV, InDel, CNV and Fusion) and homologous recombination deficiency (HRD).
  • In addition, it provides targeted therapy options and related hereditary cancer risk assessment.